What Is New - Systemic Lupus Erythematosus (SLE)

Take a look at our 'What is new' highlights in systemic lupus erythematosus (SLE)!

December 2022

"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial"

Why WINS?

Proliferative lupus nephritis (LN) can lead to renal failure. In patients with LN, after the induction phase of immunosuppressive therapy (IST), maintenance IST aims to prevent LN relapses. The optimal duration of maintenance IST remains unknown. While current 2019 EULAR/ERA–EDTA recommendations and 2021 KDIGO guidelines are largely based on experts opinion, WIN-Lupus is the first randomised controlled trial testing different durations of IST in proliferative LN. Non-inferiority of maintenance IST discontinuation after 2‒3 years was not demonstrated and patients who discontinued IST had a higher risk of severe flares of lupus. However, the majority of patients who discontinued IST did not experience a flare. Results from the WIN-Lupus study add a significant knowledge regarding the role of histological reassessment in identifying patients who can be safely weaned off maintenance IST.

Interactive question

What are the challenges of identifying patients who can be safely weaned from IST?

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

November 2022

" Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports "

Why WINS?

The data on the use of belimumab in pregnancy and any associated risk of birth defects and pregnancy loss is very limited. This study provides information about birth defects and pregnancy losses among women exposed to belimumab during pregnancy. Overall, among pregnancies ending in live birth, the numbers of birth defects in belimumab exposed pregnancies were 5.6% in clinical trials, 21.7%, ad hoc 95% CI 9.8% to 33.7% and 0% in the BPR prospective and retrospective cohorts, respectively , and 1.1% in the postmarketing/spontaneous reports, with no consistent pattern of malformations. The numbers of pregnancy losses 31.8% in clinical trials, 4.2%, ad hoc 95%CI 0.0 to 9.8% and 50.0% in the BPR prospective and retrospective cohorts, respectively, and 31.4% in the postmarketing/spontaneous reports.

Interactive question

Do you have any cases of exposure to belimumab during pregnancy?

yes / no

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

October 2022

" Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus "

Why WINS?

This study evaluates the efficacy of anti-CD19 compassionate-use chimeric antigen receptor (CAR) T cell therapy in 5 patients with SLE refractory to several immunosuppressive drugs with a median SLEDAI of 16. CAR T cells led to improvement of clinical symptoms and laboratory parameters including seroconversion of anti-double-stranded DNA antibodies. All 5 patients achieved remission of SLE according to DORIS criteria after 3 months and the median SLEDAI score after 3 months was 0. Drug-free remission was maintained during longer follow-up median of 8 months after CAR T cell administration. These data suggest that CD19 CAR T cell transfer is highly effective in SLE and provides new therapeutic possibilities to control SLE disease activity using autologous cells however,.

Interactive question

Do you think anti-CD19 CAR-T cell therapy will be a game-changing treatment for SLE patients?

yes / no

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

Sep 2022

"Interleukin-13 Receptor α1-Mediated Signaling Regulates Age-Associated/Autoimmune B Cell Expansion and Lupus Pathogenesis"

Why WINS?

IL-13 receptor α1 (IL-13Rα1) which is an X-linked receptor that transmits IL-4/IL-13 signals, is seemed affecting regulation of Age-associated/autoimmune B cells (ABCs) through interleukin-21 (IL- 21) signaling and its interplay with interferon-γ and IL-4. Human research may be conducted on this pathway to investigate sex differeneces in SLE and the data can translate into a potential target for new drug discoveries in the future.

Interactive question

Can IL-13Rα1 and related signaling pathway be one of the factors to explain sex differences in SLE? Furthermore, can it be a potential target for SLE through ABCs?

yes / no

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

"Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous hematopoietic stem cell transplantation"

Why WINS?

This study evaluates chest HRCT, lung function and skin score in SSc patients after haematopoietic stem cell transplantation (aHSCT), showing a significant improvement in extent of ILD 24 months after aHSCT, whilst esophageal dilatation and volume worsened. 78% of SSc patients reached radiological response 24 months after aHSCT. This study offers real-world data about the use of aHSCT in early SSc.

Interactive question

What is your experience with haematopoietic stem cell transplantation in systemic sclerosis?

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

May 2022

"Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren's syndrome"

Why WINS?

This omic data illuminated affinity maturation related ANA and RF repertoires findings for the molecular mechanisms of autoreactivity, lymphomagenesis and rituximab response in SjS.

Interactive question

Are novel potential biomarkers derived from this proteomic data promising to be introduced in routine clinical practice for prediction of lymphomagenesis in SjS patients?

Agree / Disagree

Join the discussion on twitter... Share your response with us using the hastag   #WhatIsNew  and tag us  @EMEUNET

 

"Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus"

Why WINS?

The impact of immunosuppressive drugs on immunogenicity of SARS-CoV-2 vaccine has been one of the main concerns in the management of SLE patients during the pandemic. In this study, the analysis of individual drug effect showed improved seroconversion in HCQ monotherapy, while MMF and prednisone were associated with a lower vaccine response in SLE patients compared to controls.

Interactive question

Have you considered temporary withdrawal of MMF prior to SARS-CoV-2 vaccine in SLE patients?

yes/no

Join the discussion on twitter... Share your response with us using the hastag   #WhatIsNew  and tag us  @EMEUNET

 

April 2022

March 2022

November 2021

October 2021

Jan 2021

December 2020

November 2020

October 2020

Sept 2020

February 2020

Jan 2020

December 2019

Nov 2019

Sept 2019

Aug 2019

July 2019

June 2019

May 2019

April 2019

March 2019

February 2019

Jan 2019

December 2018

Nov 2018

October 2018

Sept 2018

Click here  to be directed to the article by Doria et al (2018).

Click here  to be directed to the article by Putterman et al (2018).

Aug 2018

Click here  to be directed to the article by Recke et al (2018).

Click here  to be directed to the article by Romano et al (2018).

July 2018

Click here  to be directed to the article by Sciasca et al (2018).

Click here  to be directed to the article by Toro-Dominguez et al (2018).

June 2018

Click here  to be directed to the article by Birnbaum et al (2018).

Click here  to be directed to the article by Ulff-Møller et al (2018).

May 2018

Click here to be directed to the article by Rodríguez-Pintó et al (2018).

Click here to be directed to the article by Imgenberg-Kreuz et al (2018).

April 2018

Click here  to be directed to the article by Herrick et al (2018).

Click here  to be directed to the article by Greiling et al (2018).

March 2018

Click here  to be directed to the article by Zhang et al (2018).

Click here  to be directed to the article by Taher et al (2018).

February 2018

Click here  to be directed to the article by Barbhaiya et al (2018).

Click here  to be directed to the article by Kim et al (2018).

Jan 2018

Click here  to be directed to the article by Sanchez et al (2017).

Click here  to be directed to the article by Ekinci et al (2017).

December 2017

Click  here  to be directed to the article by Tjarnlund et al (2017).

Click  here  to be directed to the article by Schonau et al (2017).

November 2017

Click here  to be directed to the article by Ordi-Ros et al (2017).

Click here  to be directed to the article by Khanna et al (2017).


October 2017

Click here  to be directed to the article by Elhai et al (2017).

Click here  to be directed to the article by Huang et al (2017).